SAN DIEGO — (BUSINESS WIRE) — SynteractHCR heeft Dr. Dieter Seitz-Tutter aangetrokken als vicepresident voor de afdeling global clinical opertaions. Deze nieuwe functie is opgericht om de verdere groei van het bedrijf te accomoderen, terwijl SynteractHCR zijn bereik vergroot door geneesmiddelenontwikkelingsprogramma’s van kleine tot middelgrote biofarmaceutische bedrijven te ondersteunen.
Sietz-Tutter treedt toe tot het managementteam en zal proactief helpen bij het maken van een goede planning, uitvoering, patiëntveiligheid, datakwaliteit en alle processen die belangrijk zijn voor klinische ontwikkeling. Hij zal de ervaren klinische operationele teams leiden, onderwijl zorgend voor een goede communicatie tussen SynteractHCR, onderzoekslocaties en de sponsor.
SynteractHCR Appoints Vice President of Global Clinical Operations
SAN DIEGO–(BUSINESS WIRE)– SynteractHCR has hired Dr. Dieter Seitz-Tutter as vice president, global clinical operations. This new position was established to accommodate the continued growth of the company as SynteractHCR extends its reach supporting the drug development programs of small to mid-sized biopharma companies.
Sietz-Tutter will join the senior management team, helping to proactively ensure proper planning, conduct, patient safety, data quality, and all processes critical to clinical development. He will lead the company’s experienced clinical operations teams while fostering good communication between SynteractHCR, study sites and the sponsor.
“Dieter’s extensive experience in the CRO industry and his knowledge of the global clinical market are very valuable to our clients. He knows the emphasis we place on studies being completed successfully—on time, within budget, and in compliance with regulatory requirements,” said Wendel Barr, CEO. “We are pleased to add his industry and clinical expertise to our seasoned leadership team.”
Seitz-Tutter has more than 25 years of experience in clinical research—20 of which he spent in the CRO industry. Most recently, Seitz-Tutter was vice president of global clinical development at Chiltern where he was responsible for all clinical and country operations outside of North America. He also served as vice president for Europe at Medpace where he was responsible for clinical operations in 17 countries across Europe and Israel. Earlier in his career, he spent 13 years at Kendle where he served in different roles, including director of business development Europe, managing director Germany and vice president global clinical development Europe.
Dr. Seitz-Tutter holds a Master of Science and Doctor of Science degree in biology from Ludwig Maximilian University of Munich. He will work from the SynteractHCR Munich office.
SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “ Shared Work – Shared Vision” philosophy and ICD+ approach, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data so clients get to decision points faster.
Amanda Whitlock, 760-230-2424